1 / 26

CRYSTAL ARTHRITIS

CRYSTAL ARTHRITIS. Mark Jarek MD,FACP,FACR. CRYSTAL ARTHRITIS. GOUT (monosodium urate) PSEUDOGOUT (calcium pyrophosphate) HYDROXYAPATITE. GOUT . Inflammatory arthritis mediated by the crystallization of uric acid within joints, tophi Often associated with hyperuricemia

rubaina
Download Presentation

CRYSTAL ARTHRITIS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. CRYSTAL ARTHRITIS Mark Jarek MD,FACP,FACR

  2. CRYSTAL ARTHRITIS • GOUT (monosodium urate) • PSEUDOGOUT (calcium pyrophosphate) • HYDROXYAPATITE

  3. GOUT • Inflammatory arthritis mediated by the crystallization of uric acid within joints, tophi • Often associated with hyperuricemia • Prevalence in US =2.7% (6 million) • Incidence: 62.3 /100,000 (2-fold increase) • Associations: DM, HTN, metabolic syndrome, obesity, CVD, renal stones, CPPD • Risk Factors: genetics, age, CRF, serum uric acid, diet, alcohol, medications

  4. MEDS- Increased Urate Pool • DIURETICS (RR 1.77, CI 1.4-2.2) • Low Dose salicylates • B-blockers • PZA, ethambutol • Cyclosporin, tacrolimus • Insulin

  5. MEDS- Decreased Urate Pool • High dose Salicylate • Losartan • Fenofibrate • Amlodipine • Vitamin C • Probenecid, sulfinpyrazone, benzbromarone • Allopurinol, uricase, febuxostat

  6. Hyperuricemia – Preclinical Period • 6.8mg/dl based on urate supersaturation • 5-8 % - most asymptomatic – 20% get gout • Onset males age 30, females postmenopausal • Duration 10-15 yrs before “gout” • 80% due to undersecretion, 20% due to overproduction • Determined by 24 hr urine collection

  7. GOUT • Urate precipitation leads to acute gouty arthritis • Local factors – temperature, pH, trauma, joint hydration • Systemic factors – hydration state, fevers, meds, alcohol, co-morbid conditions • Attack resolves spontaneously 10-15 days

  8. GOUT • ACUTE GOUT • First attack 4th-6th decade for men • Women almost always postmenopausal • Classically monoarticular LE– podagra (50%), (vs pseudopodogra) >ankle >gonagra >upper extremity. • Proximal joint, central arthropathy uncommon

  9. Diagnosis • Evidence-based medicine based on EULAR (ESCISIT) – 10 key points • Acute attack 6-12 peak intensity with S/W/E/T • Aspiration always recommended if possible • Prompt polarized microscopic analysis performed • Definitive Dx – requires crystal confirmation • Gout and Sepsis can coexist – fluid should be sent Gram’s stain, culture • Serum uric acid levels neither confirm nor exclude gout • Radiographs not necessary • Risk factor assessment

  10. ACUTE GOUT • THERAPY (for all crystal diseases): • Corticosteroids: intrarticular > systemic • NSAIDs – fast acting full dose if no contraindications • Colchicine (PO,IV route dangerous) • narrow therapeutic window • Bone marrow suppression, myopathy, neuropathy • purgative effects – “Pt often run before they walk” • ACTH • NEVER ALLOPURINOL

  11. Intercritical Period • 70% prevelance of MSU crystals remain in the joint • Lasts months to years for 75-80%, 20% never have another attack

  12. Uric Acid Lowering Therapy • Lifestyle, dietary modification • Diet high in vegetables, dairy, water beneficial • Initiate uric acid lowering therapy after 1(?) or 2 episodes of acute gouty arthritis • Always prophylaxis for first 6 months with low dose steroids, NSAIDs, or colchicine

  13. URICOSURICS • Uricosurics • probenecid 1-3 grams / day • sulfinpyrazone 200-400 mg / day • Benzbromarone 100-200 mg / day (not available)

  14. URICOSURICS • Contraindications • Tophi • CRI (GFR >35ml/min) • H/O urolithiasis • Intolerance • Rapid cell turnover states • 25% failure rate – mild CRI • Interact with ASA, NSAIDs, PCN, captopril • Watch for rash , GI,HA, dyscrasias,nephrosis

  15. Uricostatic Drugs • Allopurinol - developed 1957 • Reduce annual gout attacks 4.4 to .06 / yr • Gradual resolution of tophi w/ uric acid < 6 • Titrate dose up to 600 mg /day • Uncreased toxicity with CRI • Allopurinol hypersensitivity rxn –rare but can be fatal • Densensitization can be useful for mild SEs • Oxypurinol is an option but 50% intolerance • Multiple interactions – imuran, 6MP, warfarin, theophylline, ampiciliin, diuretics • Treatment is lifelong

  16. URICOSTATICS • FEBUXOSTAT • Not yet FDA approved • ?? Hepatic toxicity, HA, diarrhea • 80-120 day safer, more effective • No dose reduction for renal, hepatic insufficiency • Combination uricourics and uricostatics offer additional benefit • URICASE – converts uric acid to allantoin • Recombinant uric acid oxidase – RASURICASE • parenteral route – can be given only once due to antibody production • Black box warning – anaphylaxis, hemolysis, methemoglobinemia • Pegylated preparation approved for urate nephropathy in tumor lysis syndrome. • Expensive • Sq administration • Fenofibrate, Lozartan • E3040 – new class of antiinflammatory compounds • Y-700, scopoletin

  17. CHRONIC GOUT • USUALLY PRESENT AFTER 10 YEARS OF ACUTE INTERMITTANT GOUT • TOPHI DEPOSITION • CHRONIC SWOLLEN JOINTS • JOINT DESTRUCTION • ABSOLUTELY REQUIRES ALLOPURINOL

  18. CHRONIC GOUT

  19. CPPD DISEASE

  20. CPPD Presentations • Acute Pseudogout • Positive birefringent rod shaped crystals • More likely in OA joint – knee> wrist> MCPs> hips,shoulders,ankles • Pseudo-rheumatoid pattern • Osteoarthritis with/out pseudogout • Chondrocalcinosis • Neuropathic joint • Tumoral CPPD deposition

  21. CPPD Presentations • Acute Pseudogout • Positive birefringent rod shaped crystals • More likely in OA joint – knee> wrist> MCPs> hips,shoulders,ankles • Pseudo-rheumatoid pattern • Osteoarthritis with/out pseudogout • Chondrocalcinosis • Neuropathic joint • Tumoral CPPD deposition

  22. CPPD Presentations • Acute Pseudogout • Positive birefringent rod shaped crystals • More likely in OA joint – knee> wrist> MCPs> hips,shoulders,ankles • Pseudo-rheumatoid pattern • Osteoarthritis with/out pseudogout • Chondrocalcinosis • Neuropathic joint • Tumoral CPPD deposition

  23. PSEUDOGOUT • HYPERPARATHYROIDISM • HEMOCHROMATOSIS • HYPOTHYROIDISM • HYPOMAGNESIEMIA • HYPERCALCEMIA • HYPOPHOPHATASIA

  24. CPPD Associations • Chondrocalcinosis • Heriditary (rarely )

  25. Basic Calcium Phosphate BCP Dz • Usually in the form of hydroxyapatite • Age related arthropathy except for pseudopodagra in young women • “Milwaukee Shoulder” • Calcific Periarthritis • Soft tissue calcification • Osteoarthritis (found in 70% of OA synovial fluid)

  26. BCP Long-Term Treatment • ? Role for bisphosphonates • ? Role for low dose warfarin

More Related